Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Front Immunol ; 13: 938306, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36311755

RESUMEN

Epidermolysis bullosa acquisita (EBA) is a subepidermal autoimmune bullous disease caused by autoantibodies targeting type VII collagen (COL7). It is characterized by inflammation and subepidermal blistering mainly through immune complex (IC)-mediated activation of neutrophils. In experimental EBA, binding of neutrophils to ICs in the skin and induction of clinical disease depends on the expression of the Fc gamma receptor (FcγR) IV. As activating FcγR mediate both neutrophil extravasation and activation, we used multiphoton imaging to obtain further insights into the mechanistic contribution of FcγRIV in the pathogenesis of EBA. First, we demonstrated that blocking FcγRIV function completely protects LysM-eGFP mice against induction of antibody transfer-induced EBA. To visualize the interactions of anti-COL7 IgG and neutrophils in vivo, fluorescently labeled anti-COL7 IgG was injected into LysM-eGFP mice. Multiphoton microscopy was sequentially performed over a period of 8 days. At all time points, we observed a significantly higher extravasation of neutrophils into the skin of mice treated with anti-FcγRIV antibody compared to controls. However, the percentage of detected neutrophils localized to the target antigen along the dermal-epidermal junction was comparable between both groups. Additionally, reactive oxygen release and migration in vitro assay data demonstrate that FcγRIV antibody treatment inhibits the activation, but not the migration, of neutrophils. Our findings underscore the importance of advanced in vivo imaging techniques to understand the complexity of IC-mediated neutrophil-dependent inflammation, and indicate that the therapeutic utility of FcγRIV blockade is achieved through impairment of IC-mediated neutrophil activation.


Asunto(s)
Epidermólisis Ampollosa Adquirida , Ratones , Animales , Activación Neutrófila , Complejo Antígeno-Anticuerpo/uso terapéutico , Modelos Animales de Enfermedad , Receptores de IgG/genética , Inflamación , Inmunoglobulina G
2.
Nat Commun ; 8(1): 1623, 2017 11 20.
Artículo en Inglés | MEDLINE | ID: mdl-29158488

RESUMEN

Efficient cell membrane repair mechanisms are essential for maintaining membrane integrity and thus for cell life. Here we show that the Ca2+- and phospholipid-binding proteins annexin A4 and A6 are involved in plasma membrane repair and needed for rapid closure of micron-size holes. We demonstrate that annexin A4 binds to artificial membranes and generates curvature force initiated from free edges, whereas annexin A6 induces constriction force. In cells, plasma membrane injury and Ca2+ influx recruit annexin A4 to the vicinity of membrane wound edges where its homo-trimerization leads to membrane curvature near the edges. We propose that curvature force is utilized together with annexin A6-mediated constriction force to pull the wound edges together for eventual fusion. We show that annexin A4 can counteract various plasma membrane disruptions including holes of several micrometers indicating that induction of curvature force around wound edges is an early key event in cell membrane repair.


Asunto(s)
Anexina A4/metabolismo , Anexina A6/metabolismo , Membrana Celular/química , Membrana Celular/metabolismo , Anexina A4/genética , Anexina A6/genética , Calcio/metabolismo , Membrana Celular/genética , Células HeLa , Humanos , Membranas Artificiales , Fosfolípidos/metabolismo , Cicatrización de Heridas
3.
J Invest Dermatol ; 136(10): 2003-2012, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27349864

RESUMEN

Since it is unknown whether thyroid hormones (THs) regulate mitochondrial function in human epidermis, we treated organ-cultured human skin, or isolated cultured human epidermal keratinocytes, with triiodothyronine (100 pmol/L) or thyroxine (100 nmol/L). Both THs significantly increased protein expression of the mitochondrially encoded cytochrome C oxidase I (MTCO1), complex I activity, and the number of perinuclear mitochondria. Triiodothyronine also increased mitochondrial transcription factor A (TFAM) protein expression, and thyroxine stimulated complex II/IV activity. Increased mitochondrial function can correlate with increased reactive oxygen species production, DNA damage, and accelerated tissue aging. However, THs neither raised reactive oxygen species production or matrix metalloproteinase-1, -2 and -9 activity nor decreased sirtuin1 (Sirt1) immunoreactivity. Instead, triiodothyronine increased sirtuin-1, fibrillin-1, proliferator-activated receptor-gamma 1-alpha (PGC1α), collagen I and III transcription, and thyroxine decreased cyclin-dependent kinase inhibitor 2A (p16(ink4)) expression in organ-cultured human skin. Moreover, TH treatment increased intracutaneous fibrillin-rich microfibril and collagen III deposition and decreased mammalian target of rapamycin (mTORC1/2) expression ex vivo. This identifies THs as potent endocrine stimulators of mitochondrial function in human epidermis, which down-regulates rather than enhance the expression of skin aging-related biomarkers ex vivo. Therefore, topically applied THs deserve further exploration as candidate agents for treating skin conditions characterized by reduced mitochondrial function.


Asunto(s)
Queratinocitos/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Tiroxina/administración & dosificación , Triyodotironina/administración & dosificación , Administración Cutánea , Células Cultivadas , Regulación hacia Abajo/efectos de los fármacos , Epidermis/efectos de los fármacos , Epidermis/metabolismo , Humanos , Queratinocitos/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Mitocondrias/metabolismo , Técnicas de Cultivo de Órganos , Especies Reactivas de Oxígeno/metabolismo , Envejecimiento de la Piel/fisiología , Enfermedades de la Piel/tratamiento farmacológico , Enfermedades de la Piel/patología , Tiroxina/farmacología , Triyodotironina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA